Nine variables, including the P-AML-5G groups, treatment protocol, inv(16), MinusX, Cytogenetic Complexity, FLT3_ITD, WT1 mutation, COG risk stratification system and CBFB-MYH11 fusion were potential risk factors affecting OS in the TARGET 145 (p < 0.01, Table 1). This evidence concerns the gene FLT3 and acute myeloid leukemia.